A Study of IBI362 in Participants With Type 2 Diabetes

NCT05606913 · clinicaltrials.gov ↗

PHASE3

Phase

COMPLETED

Status

731

Enrollment

INDUSTRY

Sponsor class

Conditions

Type 2 Diabetes

Interventions

DRUG: dulaglutide
DRUG: IBI362

Sponsor

Innovent Biologics (Suzhou) Co. Ltd.